Results 41 to 50 of about 820 (178)

Tenapanor: A new treatment option for hyperphosphatemia in end stage kidney disease

Journal of Pharmacy & Pharmaceutical Sciences, 2022
Purpose: This narrative review explores the currently published studies that have evaluated tenapanor for the treatment of hyperphosphatemia in end-stage kidney disease (ESKD) patients on hemodialysis.
Tiffany Lin, Akram Al-Makki, Brian Shepler   +2 more
doaj   +1 more source

Molecular mechanisms, physiological roles, and therapeutic implications of ion fluxes in bone cells: Emphasis on the cation‐Cl− cotransporters

Journal of Cellular Physiology, Volume 237, Issue 12, Page 4356-4368, December 2022., 2022
Ion transport systems in the membranes of osteoblasts and osteoclasts play a key role in bone remodeling by coordinating the movement of Ca2+, PO42−, and H+ ions in and out of the osseous matrix. Based on the evidence available, the cation‐Cl− cotransporters could act as unexpectedly important players in this regard.
Alexandre P. Garneau, Samira Slimani, Ludwig Haydock, Thy‐René Nsimba‐Batomene, Florence C.M. Préfontaine, Mathilde M. Lavoie, Laurence E. Tremblay, Marie‐Jeanne Fiola, Fabrice Mac‐Way, Paul Isenring   +9 more
wiley   +1 more source

Phosphate Frustration: Treatment Options to Complement Current Therapies

International Journal of Nephrology, Volume 2022, Issue 1, 2022., 2022
Hyperphosphatemia eventually develops in almost all patients with advanced chronic kidney disease and is associated with negative clinical outcomes. Thus, guidelines recommend targeting treatment to normal phosphate levels in patients with chronic kidney disease.
Pablo E. Pergola, Jaime Uribarri
wiley   +1 more source

THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: Transporters

British Journal of Pharmacology, Volume 178, Issue S1, Page S412-S513, October 2021., 2021
The Concise Guide to PHARMACOLOGY 2021/22 is the fifth in this series of biennial publications. The Concise Guide provides concise overviews, mostly in tabular format, of the key properties of nearly 1900 human drug targets with an emphasis on selective pharmacology (where available), plus links to the open access knowledgebase source of drug targets ...
Stephen P H Alexander, Eamonn Kelly, Alistair Mathie, John A Peters, Emma L Veale, Jane F Armstrong, Elena Faccenda, Simon D Harding, Adam J Pawson, Christopher Southan, Jamie A Davies, Laura Amarosi, Catriona M. H. Anderson, Philip Mark Beart, Stefan Broer, Paul A. Dawson, Bruno Hagenbuch, James R. Hammond, Jules C Hancox, Ken‐ichi Inui, Yoshikatsu Kanai, Stephan Kemp, Gavin Stewart, David T. Thwaites, Tiziano Verri   +24 more
wiley   +1 more source

Unusual presentation of a five‐month‐old boy with NaPi2a homozygous mutation without hyperphosphaturia: Case report and review of the literature

Clinical Case Reports, Volume 9, Issue 9, September 2021., 2021
Deletions of the NaPi2a gene and mutations in the SLC34A gene should be considered in patients with atypical presentation, without phosphaturia, with mild hypo to normal phosphatemia, and nephrocalcinosis. Abstract Deletions of the NaPi2a gene and mutations in the SLC34A gene should be considered in patients with atypical presentation, without ...
Renata Yakubov, Asaly Ayman, Adi Klein Kremer, An Bael, Machiel van den Akker   +4 more
wiley   +1 more source

The promising role of antibody drug conjugate in cancer therapy: Combining targeting ability with cytotoxicity effectively

Cancer Medicine, Volume 10, Issue 14, Page 4677-4696, July 2021., 2021
Antibody drug conjugate (ADC) has been under rapid development in recent years, the application of ADC has changed traditional treatment patterns for pan‐cancer patients and has become a great breakthrough for individualized precision treatment. We conducted this review to summarize basic characteristics, clinical progress, and challenges of ADCs to ...
Wen‐Qian Li, Han‐Fei Guo, Ling‐Yu Li, Yong‐Fei Zhang, Jiu‐Wei Cui   +4 more
wiley   +1 more source

Antibody engineering & therapeutics, the annual meeting of the antibody society December 7-10, 2015, San Diego, CA, USA [PDF]

, 2016
The 26th Antibody Engineering & Therapeutics meeting, the annual meeting of The Antibody Society united over 800 participants from all over the world in San Diego from 6-10 December 2015.
Bakker, J, Bradbury, AR, Carter, PJ, Lund-Johansen, F, Melis, JP, Pauthner, M, Reichert, JM, Ullman, C, Wurch, T, Yeung, J   +9 more
core   +1 more source

Highway to Success—Developing Advanced Polymer Therapeutics

Advanced Therapeutics, Volume 4, Issue 5, May 2021., 2021
Polymer therapeutics have the potential to be an important class of next generation medicines. Adapting and applying a successful framework for increased research and development productivity to the design and development of polymer therapeutics should improve their clinical translation.
Marianne B. Ashford, Richard M. England, Nadim Akhtar   +2 more
wiley   +1 more source

Radioimmunoterapy: a promising therapeutic approach to treat ovarian carcinoma [PDF]

, 2015
O cancro do ovário é a neoplasia ginecológica com maior índice de mortalidade entre a população do sexo feminino apesar dos consideráveis progressos verificados no seu tratamento.
Oliveira, Maria Cristina, Rodrigues, Carolina   +1 more
core   +2 more sources

Radioimmunotherapy with an 211At‐labeled anti–tissue factor antibody protected by sodium ascorbate

Cancer Science, Volume 112, Issue 5, Page 1975-1986, May 2021., 2021
Although the astatinated anti–tissue factor (TF) monoclonal antibody (mAb) was disrupted by an astatine‐211–induced radiochemical reaction, we demonstrated that the immunoconjugates eluted in 0.6 or 1.2% sodium ascorbate (SA) solution were protected from antibody denaturation, which contributed to maintaining their cellular binding and antitumor ...
Hiroki Takashima, Yoshikatsu Koga, Shino Manabe, Kazunobu Ohnuki, Ryo Tsumura, Takahiro Anzai, Nozomi Iwata, Yang Wang, Takuya Yokokita, Yukiko Komori, Daiki Mori, Sachiko Usuda, Hiromitsu Haba, Hirofumi Fujii, Yasuhiro Matsumura, Masahiro Yasunaga   +15 more
wiley   +1 more source